Protalix BioTherapeutics Announces Upcoming Financial Release
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a prominent biopharmaceutical company, has exciting news for its stakeholders. The company is set to release its financial results for the quarter ended September 30, 2024. This announcement will take place on November 14, 2024, marking an important date for investors and analysts alike.
Details About the Financial Release
Management at Protalix will host a conference call to discuss the financial outcomes and update participants on recent corporate developments and regulatory changes. This is a great opportunity for interested parties to gain insights into the company's performance and future direction.
Conference Call Information
The scheduled conference call will be conducted on Thursday, November 14, 2024, at 8:30 a.m. Eastern Standard Time. To participate, callers can dial:
- Toll Free: 1-877-423-9813
- International: 1-201-689-8573
- Israeli Toll-Free: 1-809-406-247
The conference ID for this call is 13749493, which is essential for accessing the discussion. Participants are encouraged to join at least 15 minutes early to ensure a smooth experience.
Webcast Access
For those who prefer to listen via the internet, the webcast can be accessed through the company’s events section on its investor relations page. This feature allows participants to view the presentation and follow along in real-time.
Background on Protalix BioTherapeutics
Founded with a mission to revolutionize the treatment of various diseases, Protalix BioTherapeutics utilizes its innovative ProCellEx technology for producing recombinant therapeutic proteins. This cutting-edge system has positioned Protalix as a leader in the biopharmaceutical sector. They proudly made history as the first to receive FDA approval for a product developed using a plant cell-based platform.
Key Products and Partnerships
Protalix’s flagship product, taliglucerase alfa, is used in the treatment of Gaucher disease. This product has been licensed to Pfizer for global development, except in Brazil where Protalix retains full rights. Moreover, the company’s newest product, Elfabrio, received approvals from both the FDA and the European Medicines Agency, showcasing Protalix’s commitment to bringing innovative treatments to market.
Additionally, Protalix is working in partnership with Chiesi Farmaceutici S.p.A. to advance Elfabrio on a global level. Their development pipeline is robust, featuring candidates like PRX–115, aimed at treating uncontrolled gout, and PRX–119 for NETs-related diseases. These projects highlight the company’s strategic focus on addressing significant unmet medical needs.
Stay Updated for More Information
As Protalix BioTherapeutics prepares to announce its financial results, stakeholders and the public are encouraged to stay informed about their ongoing progress in the biopharmaceutical landscape. The company's innovative approaches and essential partnerships position them well for future success in the industry.
Frequently Asked Questions
What is Protalix BioTherapeutics known for?
Protalix is recognized for developing and commercializing recombinant therapeutic proteins through its proprietary plant cell-based expression system.
When will Protalix share its Q3 2024 financial results?
The financial results for Q3 2024 will be announced on November 14, 2024.
How can I participate in the conference call?
Callers can join the conference call by dialing 1-877-423-9813 for toll-free access or 1-201-689-8573 for international calls.
What products are included in Protalix's pipeline?
Protalix’s pipeline includes PRX–115 for gout and PRX–119 for NETs-related diseases, demonstrating their focus on addressing significant health issues.
Where can I find more information about Protalix's events?
For updates on Protalix's events and announcements, you can visit their investor relations page on the company’s website.
